Human immunodeficiency virus protease inhibitors

Pharmacotherapy

Volumn 19, Issue 1 I, 1999, Pages 35-59

  Rana, Khurram Z ^a,c   Dudley, Michael N ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Microcide Pharmaceuticals   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; ALPRAZOLAM; AMPRENAVIR; CLARITHROMYCIN; DELAVIRDINE; DESIPRAMINE; DIDANOSINE; EFAVIRENZ; ETHINYLESTRADIOL; FLUCONAZOLE; FLUOXETINE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THEOPHYLLINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ASTHENIA; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PARESTHESIA; REVIEW;

CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HUMANS; PROTEASE INHIBITORS;

EID: 0032894127     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.1.35.30513     Document Type: Review

References (205)

1. Gallo RC, Sarin PS, Gelmann EF, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983;220:865-7.
2. Barre-Sinousi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220: 868-71.
3. Hirsch MS, D'Aquila RT. Therapy for human immuno-deficiency virus infection. N Engl J Med 1993;328:1686-95.
4. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
5. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992;8:153-64.
6. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-90.
7. Peng C, Ho BK, Chang TW, Chang NT. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989;63:2550-6.
8. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA panel. JAMA 1998;280:78-86.
9. US Department of Health and Human Services, Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. MMWR 1998;47:43-82.
10. Delta Coordinating Committee. Delta: a randomised double-blind placebo controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
11. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
12. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine of zalcitabine in HIV-infected patients with the acquired immune deficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-1106.
13. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
14. Wlodawer A. Rational drug design: the proteinase inhibitors. Pharmacotherapy 1994;14(6 Pt 2):9S-20.
15. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985;313:277-84.
16. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985;313:450-8.
17. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma. Science 1996;272:1167-9.
18. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
19. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
20. Seelmeier S, Schmidt H, Turk V, Von der Helm K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci USA 1988;85:66-12-16.
21. Toh H, Ono M, Saigo K, Miyata T. Retroviral protease-like sequence in the yeast transposon Tyl. Nature 1985;315:691-2.
22. Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987;329:351-3.
23. Abdel-Meguid SS. Inhibitors of aspartyl proteinases. Med Res Rev 1993;13:731-78.
24. Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral protease: crystal structure of a synthetic HIV-1 protease. Science 1989;245:616-21.
25. Navia MA, Fitzgerald PM, McKeever BM, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989;337:615-20.
26. Erickson NA, Neidhart DJ, VanDrie J, et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-protease. Science 1990;249:527-33.
27. Umezawa H, Aoyagi T, Morishima H, Matsuzaki M, Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J Antibiot (Tokyo) 1970;23:259-62.
28. Gross F, Lazar J, Orth H. Inhibition of the reninangiotensinogen reaction by pepstatin. Science 1972;175:656.
29. Miller RP, Poper CH, Wilson CW, DeVito E. Renin inhibition by pepstatin. Biochem Pharmacol 1972;21:2941-4.
30. BHIVA Guidelines Coordinating Committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
31. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. JAMA 1997;277:145-53.
32. Moyle GJ, Barton SE. HIV-proteinase inhibitors in the management of HIV-infection. J Antimicrob Chemother 1996;38:921-5.
33. Kempf D, Molla A, Sun E, Danner S, Boucher C, Leonard J. The duration of viral suppression is predicted by viral load during protease inhibitor therapy [abstr]. In: Program and abstracts of the 4th conference on relroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:176.
34. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989;321: 726-38.
35. Kazanjian PH, Adams DL, MacDonald L, Newman GW. Effect of antiviral agents on HIV replication in macrophages isolated from HIV-infected persons [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:102.
36. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-4100.
37. Patick A, Hongmei M, Markowitz M, Ho D, Webber S. In vitro antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV-1 protease [abstr]. In: Program and abstracts of the 2nd national conference on human retrovirus and related infections. Washington, DC: American Society for Micorbiology, 1995:88.
38. Kempf DJ, Marsh KC, Denisson JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-8.
39. Craig JC, Duncan IB, Hockley D, Greif C, Roberts NA, Mills JS. Antiviral properties of Ro-31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991;16:295-305.
40. Craig JC, Grief C, Mills JS, Hockley D, Duncan IB, Roberts NA. Effects of a specific inhibitor of HIV proteinase Ro 31-8959 on virus maturation in a chronically infected promonocytic cell line U1. Antiviral Chem Chemother 1991;2:181-6.
41. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
42. Merck & Co. Crixivan (indinavir) product information brochure. West Point, PA;1996.
43. Agouron Pharmaceuticals. Viracept (nelfinavir) product information brochure. La Jolla, CA;1997.
44. Abbott Laboratories. Norvir (ritonavir) product information brochure. Chicago, IL;1995.
45. Hoffmann-La Roche. Invirase (saquinavir) product information brochure. Nutley, NJ;1995.
46. Hoffmann-La Roche. Fortovase (saquinavir) product information brochure. Nutley, NJ;1997.
47. Granneman GR, Hsu A, Sun E, et al. Pharmacokinetics/ pharmacodynamics of ritonavir-saquinavir combination therapy [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:177.
48. Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of BID and TID dosing of Viracept in combination with stavudine (d4T) and lamivudine (3TC) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:148.
49. Sension M, Elion R, Green L, Lindquist C, Richardson W, Becker M. An open label study to assess the 48-week efficacy and safety of BID Viracept (nelfinavir mesylate) combined with 2 NRTI's in HIV-infected treatment-naïve patients [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:434.
50. Farthing C, Norris D, Slater L, et al. Fortovase soft gel capsule BID regimens in combination with two nucleosides or nelfinavir plus one nucleoside in HIV-1 infected patients [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:394.
51. Hsu A, Granneman GR, Sun E, et al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
52. Carr A, Samara K, Burton S, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:156.
53. Rosenberg HE, Mulder J, Sepkowitz KA, Giordano MF. "Protease-paunch" in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:156.
54. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV-infected patients on antiretroviral therapy (abstract 409). In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:156.
55. Keruly JC, Chiasson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:157.
56. Dong BJ, Gruta C, Legg J, Balano K, Goldschmitt RH. Diabetes and use of protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:157.
57. Nelson MR, Moyle G, Newell A, Feher M, Gazzard BG. The incidence of hyperlipidemia with protease inhibitors [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:389.
58. Rothstein AM, Caldwell RD, Allmon C, Zolopa AR, Montoya JG. Investigation of protease inhibitor-associated hypercholesterolemia in a university-based HIV clinic [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:390.
59. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;352:1881-3.
60. Sommadassi JP, Schinazi RF, McMillan A, Xie M, Bryant M. A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake [abstr]. In: Program and abstracts of the 2nd national conference on human retrovirus and related infections. Washington, DC: American Society for Microbiology, 1995:167.
61. Mummaneni V, Kaul S, Knupp CA. Single oral dose pharmacokinetic interaction study of didanosine and indinavir sulfate in healthy subjects. J Clin Pharmacol 1997;37:865.
62. Stein DS, Fish DG, Chodakewitz J, et al. A 24 week open label phase 1 evaluation of the HIV protease inhibitor L735524 [abstr]. In: Program and abstracts of the 2nd national conference on human retrovirus and related infections. Washington, DC: American Society for Microbiology, 1995:167.
63. Kovach DA, Smead J. Increased incidence of indinavir-associated nephrolithiasis in a warm climate [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:381.
64. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, and inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
65. Bertz R, Shi H, Cavanaugh J, Hsu A. Effect of three vehicles Advera, Ensure and chocolate milk on the bioavailability of an oral liquid formulation of Norvir' (ritonavir) [abstr]. In: Program of the 35th interscience conference on antimicrobial agents and chemotherapy. New Orleans: American Society for Microbiology, 1996:5.
66. Markowitz M, Saag M, Powderly W, et al. A preliminary study of ritonavir, and inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
67. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
68. Piscitelli SC, Flexner C, Minor J, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
69. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.
70. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8.
71. Everson RE, Weidle PJ, Perdue BE, Bozek PS. Evaluation of drug interactions with indinavir [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:177.
72. Kerr B, Lee C, Yuen G, et al. Overview of in vitro and in vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:133.
73. Hsu A, Granneman GR, Japour A, et al. Evaluation of potential ritonavir and indinavir combination bid regimens [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercan Society for Microbiology, 1997:12.
74. McCrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:177.
75. Buss N, and the Fortovase Study Group. Saquinavir soft gel capsule (Fortovase) pharmacokinetics and drug interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:145.
76. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate increases saquinavir soft-gel capsule exposure in HIV-positive patients [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:132.
77. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:133.
78. Morse GD, Shelton MJ, Hewitt RG, et al. Ritonavir pharmacokinetics during combination therapy with delavirdine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:143.
79. Cox SR, Schneck DW, Herman BD, et al. Delavirdine and nelfinavir: a pharmacokinetic drug-drug interaction study in healthy adult volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:144.
80. Fiske WD, Benedek IH, White SJ, Pepperess KA, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:144.
81. Skowron G, Leoung G, Dusek A, et al. Stavudine (d4T), nelfinavir and nevirapine: preliminary safety, activity and pharmacokinetic interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:145.
82. Murphy R, Gagnier P, Lamson M, Dusek A, Ju W, Hsu A. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:133.
83. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir and nevirapine [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:178.
84. Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
85. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients [abstr]. In: Program of the 35th interscience conference on antimicrobial agents and chemotherapy. New Orleans: American Society for Microbiology, 1996:6.
86. The Indinavir Pharmacokinetic Study Group. Indinavir (MK639) drug interaction studies [abstr]). In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
87. Bertz R, Wong C, Carothers L, Lauva I, Dennis S, Valdes J. Evaluation of the pharmacokinetics of multiple dose ritonavir and ketoconazole in combination [abstr]. Clin Pharm Ther 1998;63:230.
88. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:211.
89. De Wit S, Turner D, Debier M, et al. Absence of interaction between indinavir and fluconazole; a pharmacokinetic study in HIV patients [abstr]. In: Program of the 35th interscience conference on antimicrobial agents and chemotherapy. New Orleans: American Society for Microbiology, 1996:5.
90. Frye R, Bertz R, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:12.
91. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of desipramine [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
92. Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
93. Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:145.
94. Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
95. Roxane Laboratories. Viramune product information brochure. Columbus, OH;1996.
96. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
97. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:211.
98. Cato A, Qian j, Carothers L, et al. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine. Clin Pharm Ther 1996;59:144.
99. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
100. Race E, Reimann K, Letvin N, Japour A. Recurrence of trimethoprim-sulfamethoxazole hypersensitivity following initiation of protease inhibitor in patients with advanced HIV-1 [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:164.
101. Steigbigel RT, Berry R, Mellors J, et al. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK639) at escalating dose [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:80.
102. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
103. Massari F, Conant M, Mellors J, et al. A phase II open-label, randomized study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:90.
104. de Truchis P, Zucman D, Dupont C, et al. Combination therapy with D4T + 3TC + indinavir in nucleosides-experienced HIV-infected patients: an open-label study [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:109.
105. 3 - 60 week follow up [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:145.
106. Harris M, Whaley M, De Wet JJ, et al. 1 year followup of HIV patients treated with nevirapine, indinavir, and lamivudine in combination [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:160.
107. Harris M, Durakovic C, Conway B, Fransen S, Shillington A, Montaner JSG. A pilot study of indinavir, nevirapine, and 3TC in patients with advanced HIV disease [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:107.
108. Gerstoft J, and the AVANTI Study Group. AVANTI 2. A randomised, double blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs AZT/3TC/indinavir in antiretroviral naïve [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:259.
109. Piketty C, Castiel P, Gilquin J, et al. Prospective follow-up of 177 HIV-infected patients treated with indinavir in combination with nucleoside analogues [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:261.
110. Knetchen H, Mans-Peine G, Braun P. Combination therapy with stavudine (d4T), lamivudine (3TC) and indinavir in antiretroviral naïve and experienced HIV infected patients [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:263.
111. Bellman PC. Adding delavirdine to the therapy of patients failing multiple drug treatment including protease inhibitors resulted in a sustained improvement in viral load [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:275.
112. Nguyen B-Y, Haas DW, Ramirez-Ronda C, et al. Thirty two week follow-up of indinavir sulfate administered Q8 hours versus Q12 hours in combination with zidovudine and lamivudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:149.
113. 3 [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:149.
114. Squires K, Gulick R, Santana J, et al. An open-label, randomized, comparative study of d4T+3TC+indinavir versus ZDV+3TC+indinavir in treatment naïve HIV-infected patients. START 1 [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:150.
115. Eron J, Peterson D, Murphy R, et al. An open-label, randomized, comparative study of d4T+ddI+indinavir versus ZDV+3TC+indinavir in treatment naïve HIV-infected patients. START II [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:150.
116. Lawrence J, Schapiro J, Winters M, et al. Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:158.
117. Havlir D, Hicks C, Kahn J, et al. Durability of antiviral activity of efavirenz in combination with indinavir [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:395.
118. Morales-Ramirez J, Tashima K, Hardy D, et al. A phase III, multicenter randomized, open label study to compare the antiviral activity and lolerability of efavirenz + indinavir versus efavirenz + zidovudine + lamivudine versus indinavir + lamivudine at > 36 weeks [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:394.
119. Myers RA, Blick G, Shepp D, et al. Randomized study of adefovir dipivoxil in combinations with indinavir and reverse transcriptase inhibitors for treatment-naïve HIV-infected patients [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:396.
120. Haas DW, Fessel WJ, Delapenha RA, et al. A phase I, double-blind, placebo-controlled, multi-center study to determine the effectiveness and tolerability of the combination of efavirenz and indinavir versus indinavir in HIV-1 infected patients receiving nucleoside analogue therapy at > 36 weeks [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:441.
121. Pednault L, Elion R, Adler M, et al. Stavudine (d4T), didanosine (ddI) and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:108.
122. Gathe J Jr, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs Stavudine (d4T) alone [abstr]. In: Program and abstracts of the 11th international conference on on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
123. Markowitz M, Cao Y, Hurley A, et al. Virologic and immunologic response to triple therapy with nelfinavir in combination with AZT/3TC in 12 antiretroviral naïve HIV-infected subjects at 20 months [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:148.
124. Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y. Analysis of long-term virologic data from the Viracept 511 protocol using 3 HIV-RNA assays [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:148.
125. Petersen A, Johnson M. Longterm comparison of BID and TID dosing Viracept (nelfinavir) in combination with stavudine (d4T) and lamivudine (3TC) in HIV patients [abstr]. In: Program and abstracts of the 12th world AIDS conference. Geneva: 12th World AIDS Conference, 1998.
126. Kagan S, Jemsek J, Martin DG, et al. Initial effectiveness and tolerability of nelfinavir in combination with efavirenz in antiretroviral therapy naïve or nucleoside analogue experienced HIV-1 infected patients: characterization in a phase II, open-label, multi-center study at > 36 weeks [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:432.
127. Heath-Chiozzi M, Leonard J, Henry D, et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:162.
128. Mathez D, de Truchis P, Gorin I, et al. Ritonavir, AZT, ddC as a triple combination in AIDS patients [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infection. Washington, DC: Infectious Disease Society of America, 1996:106.
129. Saimot AG, Landman R, Damond F, et al. Ritonavir, stavudine (d4T), didanosine (ddI) as a triple combination treatment in antiretroviral-naïve patients [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:109.
130. Hoen B, Dumon B, Harzic M, et al. Efficacy of zidovudine, lamivudine and ritonavir combination in patients with symptomatic primary HIV-1 infection: the ANRS 053/53B trial [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:260.
131. Opravil M, Pennekamp A, Huber W, et al. EARTH study: AZT+3TC vs. AZT+3TC+ ritonavir in asymptomatic patients with early HIV infection [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:260.
132. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334: 1011-17.
133. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
134. Sension M, Farthing C, Palmer Pattison T, Pilson R, Siemon-Hryczyk P.
135. Slater L, on behalf of the NV15355 Study Group. Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naïve patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:148.
136. Cohen C, Sun E, Cameron W, et al. Ritonavir-saquinavir combination treatment in HIV-infected patients [abstr]. In: Program addendum of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:8.
137. Kaufmann G, Duncombe C, Beveridge A, et al. Efficacy of a four drug combination therapy including two protease inhibitors in patients with advanced HIV-1 illness [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:281.
138. Puig T, Bonjoch A, Ruiz L, et al. Usefulness of ritonavir and saquinavir combination therapy for HIV-advanced patients failing on indinavir [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:281.
139. Michelet C, Bellissant E, Delfraissy JF, et al. Safety and efficacy of a combination of ritonavir and saquinavir added to AZT+3TC in HIV infected patients, pilot study, ANRS 069 [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:281.
140. Battegay M, Bernasconi E, Flepp M, et al. A pilot study of saquinavir in combination with ritonavir and d4T in patients with advanced HIV disease [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:281.
141. Tebas P, Kane E, Klebert M, Simpson J, Powderly WG, Henry K. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:175.
142. Batisse D, Salmon-Seron D, Karmochkine M, et al. Efficacy and safety of ritonavir and saquinavir in combination in protease inhibitors-experienced patients [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:282.
143. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir among HIV infected adults: preliminary results from a community based study [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:282.
144. Talal A, Cao Y, Hurley A, et al. Saquinavir in combination with AZT/3TC and ritonavir: a convenient BID regimen [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:282.
145. Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naïve patients in year two of follow-up [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:152.
146. Gisolf E, Colebunders R, Van Wanzeele F, et al. Treatment with ritonavir/saquinavir/stavudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:152.
147. Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir and nelfinavir in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:152.
148. Gallant JE, Heath-Chiozzi M, Raines C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:153.
149. Opravil M, on behalf of the SPICE Study Team. Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule and nelfinavir in HIV infected individuals [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:153.
150. Kravcik S, Farnsworth A, Patick A, et al. Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:153.
151. Cassano P, Hermans P, Sommereijins B, et al. Combined quadruple therapy with ritonavir-saquinavir + nucleosides in patients who failed in triple therapy with ritonavir, saquinavir or indinavir [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:159.
152. Squires KE, Currier JS, Clark R, et al. Women first: a study of the effects of treatment in HIV-infected women with combination nelfinavir, saquinavir, stavudine, and lamivudine [abstr]. In: Program and abstracts of the 12th world AIDS conference. Geneva: 12th World AIDS Conference, 1998.
153. Rockstroh JK, Bergmann F, Wiesel W, et al. Efficacy and safety of BID firstline ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals [abstr]. In: Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego: American Society for Microbiology, 1998:432.
154. Roca-Arbones V, Saurez A, Perez-Cecilia E, Tellez MJ, Fernandez-Cruz A, Picazo JJ. Association of two nucleoside analogs and one protease inhibitor in the treatment of HIV infection in non-naïve patients [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:261.
155. Antela A, Perez-Elias MJ, Casado JL, et al. Protease inhibitor therapy in patients with advanced HIV disease and heavily pretreated: the role of saquinavir [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:278.
156. Martinez E, Gatell J, Buira E, et al. An open randomized trial comparing the effect of a triple combination therapy including d4T, 3TC and a protease inhibitor (saquinavir, ritonavir, indinavir) in adult HIV-1 infected patients previously treated with nucleoside reverse transcriptase inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:148.
157. Clumeck N, Colebunders B, Vandercam B, et al. Randomized comparative outcome trial of indinavir and ritonavir in protease inhibitor naïve HIV patients with CD4 below 100 cells/uL [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:151.
158. Borleffs JC, on behalf of the CHEESE Study Team. First comparative study of saquinavir soft gel capsules vs indinavir as part of triple therapy regimen (CHEESE) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:151.
159. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:162.
160. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase) plus HIVID (zalcitabine, ddC) [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
161. Revicki D, Swartz C. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir-zalcitabine therapy for advanced HIV-infection [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:113.
162. Data on file. Study SV14604 Executive Summary. Roche Laboratories. June 1997.
163. Lennox J, Ellerbrock TV, Palmore M, et al. Effect of antiretroviral therapy on vaginal HIV RNA level [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:107.
164. Boswell SL, Mayer KH, Goldstein RS, Tucker L, Xu C, Anderson D. The effect of HIV protease inhibitors on seminal proviral DNA [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:102.
165. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:207.
166. Manegold C, Seidlitz B, Medve M, et al. Improved proliferative function of peripheral blood mononuclear leukocytes (PBML) of HIV1-infected patients after initiation of therapeutic HIV protease inhibition [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:111.
167. Lederman M, Connick E, Landay A, et al. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir) preliminary results of ACTG 315 [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:208.
168. Autran B, Li TS, Tubiana R, et al. Restoration of CD4 T helper cell functions in advanced patients after combined anti-retroviral therapies [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:164.
169. Cavert W, Staskus K, Zupancic M, et al. Quantitative in situ hybridization (ISH) measurement of HIV-1 RNA clearance kinetics from lymphoid tissue (LT) cellular compartments during triple-drug therapy [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:207.
170. Markowitz M, Cao Y, Vesanen M, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:207.
171. Perrin L, Maikowitz M, Calandra G, et al. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:108.
172. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
173. Perelson AS, Essenger P, Markowitz M, Ho D. How long should treatment be given if we had an antiretroviral regimen that completely blocks HIV replication [abstr]. In: Program and abstracts of the 11th international conference on AIDS. Vancouver, BC, Canada: 11th International Conference on AIDS Society, 1996.
174. Norbeck D, Kumar G, Marsh K, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors [abstr]. In: Program addendum of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:9.
175. Kempf D, Marsh K, Denisson J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:79.
176. Deeks S, Grant R, Horton C, Simmonds N, Follansbee S, Eastman S. Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:282.
177. Gallant JE, Hall C, Barnett S, Raines C. Ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:151.
178. Rana KZ, Simmons KA, Dudley MN. Reduction of the IC50 of didanosine by hydroxyurea against HIV [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Toronto, Ontario: Amercian Society for Microbiology, 1997:266.
179. Gao W-Y, Johns DG, Chokekijchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7.
180. Lori F, Jessen H, Clerici M, Lieberman J, Lisziewicz J. Consistent, sustained HIV suppression without rebound by hydroxyurea, ddI and a protease inhibitor [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:203.
181. Lori F, Jessen H, Clerici M, Lieberman J, Siciliano RF, Lisziewicz J. Drugs suppressing HIV replication and cell proliferation decrease proviral DNA to undetectable levels [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:224.
182. Lisziewicz J, Jessen H, Rosenberg E, et al. Hydroxyurea containing combinations exhibit long-term efficacy, a novel resistance/rebound profile, and lead to anti-HIV specific immune response reconstitution [abstr]. In: Program and abstracts of the 12th world AIDS conference. Geneva: 12th World AIDS Conference, 1998.
183. Mueller BU, Zuckerman J, Nelson PP Jr, et al. Update on the pediatric phase I/II study of the protease inhibitor ritonavir (ABT-378) [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:198.
184. Krogstad P, Kerr B, Anderson R, et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate in HIV+ children [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:198.
185. Kimberlin DW, Coen DM, Biron KK, et al. Molecular mechanisms of antiviral resistance. Antiviral Res 1995;26:369-401.
186. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
187. Jacobsen H, Yasargil K, Winslow DL, et al. Characterisation of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206:527-34.
188. Sheldon J, Craig C, Race E, et al. Reduced sensitivity to saquinavir occurs infrequently, associates only with 48V or 90M and is modest in degree [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:103.
189. Race E, Sheldon JG, Kaye S, Gilbert SM, Moffatt AR, Duncan LB. Mutations associated with reduced sensitivity to saquinavir occur in a minority of patients treated in combination with ddC: results from a phase III clinical trial (NV14256) [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:175.
190. Jacobsen H, Haenggi M, Ott M, Duncan IB, Mous J. Resistance to saquinavir: update of genotypic analysis of phase II trials [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:236.
191. Eastman PS, Kelso R, Boyer E, et al. Loss of suppression of viral replication by ritonavir (ABT-538) is quantitatively associated with the acquisition of genotypic mutations at codon 82 of the HIV-1 protease gene [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:90.
192. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995;69:701-6.
193. Gao Q, Stewart K, Park C, et al. Specific mutations in HIV-1 protease that confer diminished susceptibility to ABT-538 [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:256.
194. Condra JH, Schleif WA, Blahy OM, et al. Mutations in HIV protease conferring resistance to inhibitor L-735,524 [abstr]. In: Program and abstracts of the 2nd national conference on human retrovirus and related infections. Washington, DC: American Society for Microbiology, 1995:88.
195. Condra JH, Gabryelski WA, Blahy OM, et al. In vivo evolution of resistance to the HIV-1 protease inhibitor indinavir [abstr]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1996:80.
196. 3 [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:235.
197. Roberts NA, Race E, Tomlinson P, Gilbert S, Duncan IB. Resistance and cross resistance issues: studies with saquinavir [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:254.
198. Murphy R, DeGruttola V, Gulick R, et al. 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347 [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:175.
199. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immuno-deficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39:1704-10.
200. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995;69:5228-35.
201. Kim EE, Dwyer MD, Thomson JA, et al. Structural analysis of the basis of viral resistance to VX-478 [abstr]. In: Program and abstracts of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco: American Society for Microbiology, 1995:255.
202. Sham H, Kempf D, Molla A, et al. Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:67.
203. Lal R, Hsu A, Granneman GR ,et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:103.
204. Molla A, Vasavanonda S, Denissen J, et al. Effect of human serum proteins on the antiretroviral activity of ritonavir and ABT-378, potent inhibitors of HIV protease [abstr]. In: Program and abstracts of the 4th conference on retroviruses and opportunistic infections. Washington, DC: Infectious Disease Society of America, 1997:104.
205. Kumar GN, Dykstra J, Jayanti V, Denissen JF. Potent inhibition of the in vitro human liver microsomal metabolism of the HIV-1 protease inhibitor ABT-378 by ritonavir-potential for a positive drug interaction [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago: Foundation for Retrovirology and Human Health, 1998:201.